General

Maculaser has been granted a Japanese patent for its method and device for determining changes in retinal and/or brain temperature. […]

Maculaser, a company developing treatments for retinal disorders that affect millions of people worldwide and that currently have no effective

Maculaser’s novel temperature-controlled subthreshold laser therapy and method for treating diabetic macular edemas is currently being presented at the world’s leading

Maculaser’s Chief Scientific Officer Teemu Turunen presented the results of our clinical usability trial in Visionarium XX, an acknowledged conference

The start of the autumn has been filled with both ophthalmology and investment events. Latest, the past two days in